INAB · In8bio, Inc.
$1.18
+0.09 (+7.80%)
At close · Oct 20
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 6, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on the Company's business strategy, its existing cash of $18.0 million as of June 30, 2026 is not anticipated to fund the Company's projected operating expenses and capital expenditure requirements for a period of at least 12 months from the date of issuance of these condensed financial statements, and accordingly, there is substantial doubt about the Company's ability to continue to operate as a going concern.”View the 10-Q filed Aug 6, 2026
Market Cap
$10.75M
Shares
9.86M
Volume · Oct 20
1713
Avg daily vol (3M)
54.47K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.09
Open$1.11
Day$1.07–1.17
52W close$0.96–2.59
Avg vol 30d45K
Short int46K · 0.5% float · 1.0d
Short vol23%
Last earningsMay 21, 2026
DataJul 2021–Oct 2026
Filing10-Q · Aug 6
Up next
Next earnings call
May 25, 2028
Est · unconfirmed
· in 83 wks
filed Aug 6, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$18.67M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$18.01M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+372.6%
Year over year · more shares
Price change (1Y)
-47.3%
Trailing year
Short interest
0.5%
Latest settlement · 1.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Weak
Sentiment
Bullish
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 18.4 · elevated
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−28%
below
Price vs 50-day avg
−7%
below
RSI (14)
38
neutral
MACD trend
Negative
52-week position
8%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+3%
trailing
6-month return
−29%
trailing
YTD return
−53%
this year
Relative strength
−36%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
+11% holders QoQ · +3 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.47% of float · ▼ -26.4% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
21 holders — mid 3-yr range
Squeeze score
32
low risk · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
85%
annualized · 1-yr
Max drawdown
−63%
past year
ATR
8.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−28%
Bearish
Price vs 50-day avg
−7%
Bearish
RSI (14)
38
Neutral
MACD trend
Negative
Bearish
52-week position
8%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
+11% holders QoQ · +3 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.47% of float · ▼ -26.4% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
21 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $1 · 8%
Range high $3
vs 200-day avg -28%
vs 50-day avg -7%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
INAB
this stock
In8bio, Inc.
|
$10.75M | -53.4% | — | — | 0.5% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.07B | +10.7% | +46.2% | 29.9 | 1.8% |
|
MRNA
Moderna, Inc.
|
$90.58B | +669.4% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.51B | +1.3% | +20.8% | 19.4 | 2.1% |
|
CSLLY
Csl Ltd
|
$64.50B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| INAB | -11.4% | +2.8% | -28.8% | -18.1% | -53.4% |
| SPY | -1.5% | -0.9% | +7.7% | +0.5% | +12.4% |
| vs SPY | -9.9% | +3.7% | -36.5% | -18.6% | -65.8% |